StockData
Kairos Pharma, LTD. logo

Kairos Pharma, LTD. (KAPA) shareholders

KAPANYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.40−0.01 (-1.70%)

Close on Nov 17, 2026Market cap $1.49MP/E –Yield –

Ownership

Who owns Kairos Pharma's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
John S. YuCEO and Chairman, Director, 10% owner5,546,67723.41%Nov 26, 2025
Neil BhowmickChief Scientific Officer1,311,7395.54%Dec 30, 2025
Doug SamuelsonChief Financial Officer293,0391.24%Nov 26, 2025
Ramachandran MuraliVP of Research and Development299,5291.26%Nov 26, 2025
Hyun W. BaeDirector73,3700.31%Dec 23, 2025
Rahul SinghviDirector49,2040.21%Nov 26, 2025
Hansoo Michael KeyoungDirector29,0840.12%Nov 26, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Neil Bhowmick
Chief Scientific Officer
Oct 8, 2025Award+171,756––1,311,739
Hyun W. Bae
Director
Oct 8, 2025Award+19,084––73,370
Rahul Singhvi
Director
Oct 8, 2025Award+19,084––49,204
Hansoo Michael Keyoung
Director
Oct 8, 2025Award+19,084––29,084
Doug Samuelson
Chief Financial Officer
Oct 8, 2025Award+152,672––293,039
Ramachandran Murali
VP of Research and Development
Oct 8, 2025Award+152,672––299,529
John S. Yu
CEO and Chairman, Director, 10% owner
Oct 8, 2025Award+190,840––230,105
Hyun W. Bae
Director
Sep 16, 2025Award+10,000––54,286
Hansoo Michael Keyoung
Director
Sep 16, 2025Award+10,000––10,000
Neil Bhowmick
Chief Scientific Officer
Jan 1, 2025Award+14,000––1,139,983
John S. Yu
CEO and Chairman, Director, 10% owner
Jan 1, 2025Award+14,000––5,355,838
Ramachandran Murali
VP of Research and Development
Jan 1, 2025Award+14,000––147,057
Ramachandran Murali
VP of Research and Development
Nov 25, 2024Buy+200$1.59$318133,057
Doug Samuelson
Chief Financial Officer
Nov 22, 2024Buy+2,500$1.50$3.75K60,796
John S. Yu
CEO and Chairman, Director, 10% owner
Nov 20, 2024Buy+4,000$1.44$5.76K5,341,837

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
2.26%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-37.5%
From 0M shares
Short volume, 20 days
23.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Kairos Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 49,276 shares on Oct 7, 2026 over the last 90 days.

See a number that looks wrong?